Agios_2021_Logo.png
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
December 08, 2024 12:40 ET | Agios Pharmaceuticals, Inc.
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
JJ_Logo_SingleLine_Red_RGB.png
TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
December 08, 2024 12:35 ET | Janssen Cilag International NV
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. ...
NOVARTIS logo.jpg
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
December 08, 2024 12:30 ET | Novartis Pharma AG
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key...
roche-logo-blue.png
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
December 08, 2024 12:30 ET | F. Hoffmann-La Roche Ltd
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse...
C4Therapeutics-Website-Logo-FullColor-(R).png
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024 12:30 ET | C4 Therapeutics, Inc.
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR);...
July 30, 2021 - ROSEN LOGO.jpg
業界領先的律師事務所 ROSEN 鼓勵 Symbotic Inc. 投資者在該公司首次提出對 SYM 證券集體訴訟的重要截止日期前聘請律師
December 08, 2024 12:11 ET | The Rosen Law Firm PA
紐約, Dec. 09, 2024 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 宣佈代表曾於 2024 年 2 月 8 日至 2024 年 11 月 26 日期間(包括首尾兩日,簡稱「集體訴訟期」)購買 Symbotic Inc. (NASDAQ: SYM) 證券的人士提出集體訴訟。 集體訴訟經已提出。...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages Symbotic Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SYM
December 08, 2024 12:11 ET | The Rosen Law Firm PA
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Symbotic...
Affimed Logo.jpg
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET | Affimed N.V.
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of...
MolecularPartners_Logo.jpg
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
December 08, 2024 12:00 ET | Molecular Partners
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process...
Cogent_Biosciences_logo_RGB.png
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 08, 2024 12:00 ET | Cogent Biosciences, Inc.
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with...